EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity

[Image: see text] Inhibitors of the protein methyltransferase Enhancer of Zeste Homolog 2 (EZH2) may have significant therapeutic potential for the treatment of B cell lymphomas and other cancer indications. The ability of the scientific community to explore fully the spectrum of EZH2-associated pat...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:ACS Med Chem Lett
Auteurs principaux: Campbell, John E., Kuntz, Kevin W., Knutson, Sarah K., Warholic, Natalie M., Keilhack, Heike, Wigle, Tim J., Raimondi, Alejandra, Klaus, Christine R., Rioux, Nathalie, Yokoi, Akira, Kawano, Satoshi, Minoshima, Yukinori, Choi, Hyeong-Wook, Porter Scott, Margaret, Waters, Nigel J., Smith, Jesse J., Chesworth, Richard, Moyer, Mikel P., Copeland, Robert A.
Format: Artigo
Langue:Inglês
Publié: American Chemical Society 2015
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4434464/
https://ncbi.nlm.nih.gov/pubmed/26005520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.5b00037
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires